NASDAQ:TRML Tourmaline Bio (TRML) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free TRML Stock Alerts $15.50 -0.18 (-1.15%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$15.30▼$16.4050-Day Range$15.09▼$45.6452-Week Range$9.18▼$48.31Volume233,518 shsAverage Volume383,231 shsMarket Capitalization$397.58 millionP/E RatioN/ADividend YieldN/APrice Target$61.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Tourmaline Bio alerts: Email Address Tourmaline Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside287.0% Upside$61.80 Price TargetShort InterestBearish11.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 3 Articles This WeekInsider TradingAcquiring Shares$3.25 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.90) to ($3.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.77 out of 5 starsMedical Sector629th out of 918 stocksBiological Products, Except Diagnostic Industry100th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingTourmaline Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTourmaline Bio has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.58% of the float of Tourmaline Bio has been sold short.Short Interest Ratio / Days to CoverTourmaline Bio has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Tourmaline Bio has recently increased by 20.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTourmaline Bio does not currently pay a dividend.Dividend GrowthTourmaline Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRML. Previous Next 1.3 News and Social Media Coverage News SentimentTourmaline Bio has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Tourmaline Bio this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for TRML on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Tourmaline Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -69% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tourmaline Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,250,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.02% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tourmaline Bio are expected to decrease in the coming year, from ($2.90) to ($3.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tourmaline Bio is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tourmaline Bio is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTourmaline Bio has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Tourmaline Bio Stock (NASDAQ:TRML)Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.Read More TRML Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRML Stock News HeadlinesApril 29, 2024 | americanbankingnews.comShort Interest in Tourmaline Bio, Inc. (NASDAQ:TRML) Expands By 20.9%March 22, 2024 | seekingalpha.comTourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly BearishApril 29, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...March 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tourmaline Bio Amidst Promising Clinical Trials and Drug Candidate ProspectsMarch 19, 2024 | investorplace.comTRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023March 19, 2024 | globenewswire.comTourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsMarch 16, 2024 | ca.finance.yahoo.comTRML Apr 2024 55.000 callMarch 15, 2024 | finance.yahoo.comTRML Apr 2024 20.000 putApril 29, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...March 15, 2024 | finance.yahoo.comTRML Apr 2024 35.000 putMarch 15, 2024 | finance.yahoo.comTRML Apr 2024 50.000 callMarch 13, 2024 | markets.businessinsider.comTruist Financial Gives a Buy Rating to Tourmaline Bio (TRML)March 12, 2024 | finance.yahoo.comTRML Mar 2024 60.000 putMarch 12, 2024 | ca.finance.yahoo.comTRML Apr 2024 25.000 putMarch 1, 2024 | investing.comTourmaline Bio Inc (TRML)March 1, 2024 | finance.yahoo.comBullish Tourmaline Bio Insiders Loaded Up On US$643.3k Of StockFebruary 28, 2024 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Tourmaline Bio (TRML)February 28, 2024 | msn.comHere's What Could Help Tourmaline Bio, Inc. (TRML) Maintain Its Recent Price StrengthFebruary 27, 2024 | globenewswire.comTourmaline Bio to Present at Upcoming Investor ConferencesFebruary 14, 2024 | finance.yahoo.comTRML Mar 2024 35.000 callFebruary 13, 2024 | finance.yahoo.comTRML Sep 2024 30.000 callFebruary 13, 2024 | finance.yahoo.comTRML Feb 2024 30.000 callFebruary 13, 2024 | finance.yahoo.comTRML Mar 2024 40.000 putFebruary 8, 2024 | msn.comWhat Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing'February 6, 2024 | finance.yahoo.comCEO Sandeep Kulkarni Buys 9650 Shares of Tourmaline Bio IncFebruary 1, 2024 | finance.yahoo.comTourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceJanuary 29, 2024 | finance.yahoo.comTourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesSee More Headlines Receive TRML Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tourmaline Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today4/29/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TRML Previous SymbolNASDAQ:TRML CUSIPN/A CIK1827506 WebN/A Phone502-398-9250FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Stock Price Target$61.80 High Stock Price Target$74.00 Low Stock Price Target$48.00 Potential Upside/Downside+286.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($11.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.86% Return on Assets-29.30% Debt Debt-to-Equity RatioN/A Current Ratio41.76 Quick Ratio41.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.08 per share Price / Book1.59Miscellaneous Outstanding Shares25,650,000Free Float22,821,000Market Cap$409.89 million OptionableOptionable Beta2.33 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Sandeep C. Kulkarni M.D. (Age 42)Co-Founder, CEO & Director Mr. Ryan Robinson CPAVP of Finance, Controller & Interim CFODr. Susan Dana Jones Ph.D.Chief Technology OfficerMr. W. Bradford Middlekauff J.D. (Age 62)Chief Business Officer & General Counsel Ms. Kimberly PiorkowskiVice President of People, Culture and ComplianceDr. Yung H. Chyung M.D. (Age 47)Chief Medical Officer Mr. Ryan IarrobinoSVP of Product DevelopmentDr. Kevin B. Johnson M.B.A.Ph.D., Chief Regulatory OfficerMs. Dora RauSenior Vice President & Head of QualityMr. Gerhard Hagn Pharm.D.Senior VP and Head of Commercial & Business DevelopmentMore ExecutivesKey CompetitorsReplimune GroupNASDAQ:REPLLexeo TherapeuticsNASDAQ:LXEOVoyager TherapeuticsNASDAQ:VYGRiTeos TherapeuticsNASDAQ:ITOSC4 TherapeuticsNASDAQ:CCCCView All CompetitorsInsiders & InstitutionsChina Universal Asset Management Co. Ltd.Bought 2,582 shares on 4/29/2024Ownership: 0.019%Denali Advisors LLCBought 5,600 shares on 4/19/2024Ownership: 0.022%Great Point Partners LLCBought 672,885 shares on 2/15/2024Ownership: 3.308%Avoro Capital Advisors LLCBought 868,407 shares on 2/14/2024Ownership: 4.269%RTW Investments LPBought 398,850 shares on 2/14/2024Ownership: 1.961%View All Insider TransactionsView All Institutional Transactions TRML Stock Analysis - Frequently Asked Questions Should I buy or sell Tourmaline Bio stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tourmaline Bio in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TRML shares. View TRML analyst ratings or view top-rated stocks. What is Tourmaline Bio's stock price target for 2024? 6 Wall Street analysts have issued 1-year target prices for Tourmaline Bio's stock. Their TRML share price targets range from $48.00 to $74.00. On average, they predict the company's share price to reach $61.80 in the next year. This suggests a possible upside of 287.0% from the stock's current price. View analysts price targets for TRML or view top-rated stocks among Wall Street analysts. How have TRML shares performed in 2024? Tourmaline Bio's stock was trading at $26.18 at the start of the year. Since then, TRML stock has decreased by 39.0% and is now trading at $15.97. View the best growth stocks for 2024 here. Are investors shorting Tourmaline Bio? Tourmaline Bio saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,790,000 shares, an increase of 20.9% from the March 31st total of 1,480,000 shares. Based on an average daily volume of 438,000 shares, the days-to-cover ratio is presently 4.1 days. Currently, 11.6% of the company's shares are short sold. View Tourmaline Bio's Short Interest. When is Tourmaline Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our TRML earnings forecast. How were Tourmaline Bio's earnings last quarter? Tourmaline Bio, Inc. (NASDAQ:TRML) released its quarterly earnings results on Tuesday, March, 19th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by $0.06. Who are Tourmaline Bio's major shareholders? Tourmaline Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Denali Advisors LLC (0.02%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Aaron Kantoff, Caley Castelein, Mark Mcdade, Parvinder Thiara and Sandeep Chidambar Kulkarni. View institutional ownership trends. How do I buy shares of Tourmaline Bio? Shares of TRML stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TRML) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
